Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
01
12
2021
accepted:
29
03
2022
entrez:
20
7
2022
pubmed:
21
7
2022
medline:
21
7
2022
Statut:
epublish
Résumé
Whether sex can influence the clinical response to biological treatment in patients with severe asthma has not been fully addressed. The aim of this study was to investigate in patients with severe asthma undergoing biological treatment the individual evolution of lung function measurements and patient-reported asthma control scores over a 12-month follow-up period, in relation to patients' sex, in different age ranges. Second, the change in the administered dose of oral corticosteroids (OCS) before and after 12 months of treatment was investigated. 64 patients (58% female and 42% male) with a median age of 52 years were enrolled in the study. There were no relevant differences between sexes in terms of lung function, patient-reported asthma control, exacerbation rate and daily OCS dose within the study timeframe. A separate sub-analysis by biological treatment confirmed the same finding. Stratifying individuals by age, we showed that older men had lower lung function parameter values (forced expiratory volume in 1 s (FEV According to our findings, sex does not act as a determinant of treatment response to biologicals in people with severe asthma. Although to be confirmed in larger studies, our data suggest that neither sex nor age should limit biological treatment prescription, once the eligibility criteria for that therapy are satisfied.
Sections du résumé
Background
UNASSIGNED
Whether sex can influence the clinical response to biological treatment in patients with severe asthma has not been fully addressed.
Aims and methods
UNASSIGNED
The aim of this study was to investigate in patients with severe asthma undergoing biological treatment the individual evolution of lung function measurements and patient-reported asthma control scores over a 12-month follow-up period, in relation to patients' sex, in different age ranges. Second, the change in the administered dose of oral corticosteroids (OCS) before and after 12 months of treatment was investigated.
Results
UNASSIGNED
64 patients (58% female and 42% male) with a median age of 52 years were enrolled in the study. There were no relevant differences between sexes in terms of lung function, patient-reported asthma control, exacerbation rate and daily OCS dose within the study timeframe. A separate sub-analysis by biological treatment confirmed the same finding. Stratifying individuals by age, we showed that older men had lower lung function parameter values (forced expiratory volume in 1 s (FEV
Conclusion
UNASSIGNED
According to our findings, sex does not act as a determinant of treatment response to biologicals in people with severe asthma. Although to be confirmed in larger studies, our data suggest that neither sex nor age should limit biological treatment prescription, once the eligibility criteria for that therapy are satisfied.
Identifiants
pubmed: 35854871
doi: 10.1183/23120541.00670-2021
pii: 00670-2021
pmc: PMC9289375
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
Biochem Pharmacol. 2020 Sep;179:113978
pubmed: 32305434
Expert Rev Respir Med. 2019 Dec;13(12):1205-1212
pubmed: 31592700
J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1
pubmed: 29800752
World Allergy Organ J. 2019 May 10;12(4):100032
pubmed: 31193146
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
pubmed: 11158037
J Allergy Clin Immunol. 2010 Sep;126(3):498-504.e1-6
pubmed: 20816186
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Allergy Asthma Proc. 2012 Nov-Dec;33(6):500-7
pubmed: 23394508
Allergy Asthma Immunol Res. 2015 Jan;7(1):83-7
pubmed: 25553267
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
J Exp Med. 2017 Jun 5;214(6):1581-1592
pubmed: 28484078
J Clin Endocrinol Metab. 1991 Nov;73(5):1016-25
pubmed: 1719016
Chest. 2020 Apr;157(4):790-804
pubmed: 31785254
J Pathol. 2007 Jan;211(2):173-80
pubmed: 17200939
Clin Mol Allergy. 2017 Apr 10;15:9
pubmed: 28400707
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1194-1200
pubmed: 33069885
Intern Med J. 2016 Sep;46(9):1054-62
pubmed: 27350385
Ann Allergy Asthma Immunol. 2003 Dec;91(6):553-8
pubmed: 14700439
Pulm Pharmacol Ther. 2014 Oct;29(1):74-9
pubmed: 24508951
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98
pubmed: 11836290
Front Immunol. 2018 Dec 18;9:2997
pubmed: 30619350
Curr Allergy Asthma Rep. 2017 Mar;17(3):19
pubmed: 28332107
Genes (Basel). 2020 Jul 02;11(7):
pubmed: 32630716
Cell Rep. 2017 Nov 28;21(9):2487-2499
pubmed: 29186686